AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.760
+0.070 (2.60%)
Sep 11, 2026, 4:00 PM EDT - Market closed
AC Immune Employees
As of December 31, 2025, AC Immune had 122 total employees, including 90 full-time and 32 part-time employees. The number of employees decreased by 50 or -29.07% compared to the previous year.
Employees
122
Change (1Y)
-50
Growth (1Y)
-29.07%
Revenue / Employee
$177,619
Profits / Employee
-$437,794
Market Cap
274.42M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | -50 | -29.07% | 90 | 32 |
| Dec 31, 2024 | 172 | 11 | 6.83% | 133 | 39 |
| Dec 31, 2023 | 161 | 5 | 3.21% | 133 | 28 |
| Dec 31, 2022 | 156 | 7 | 4.70% | 126 | 30 |
| Dec 31, 2020 | 149 | 17 | 12.88% | 125 | 24 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| ProQR Therapeutics | 187 |
| Fate Therapeutics | 161 |
| Sutro Biopharma | 128 |
| Foghorn Therapeutics | 106 |
| Immuneering | 57 |
| Pyxis Oncology | 56 |
| ALX Oncology Holdings | 48 |
ACIU News
- 24 days ago - AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - GlobeNewsWire
- 4 weeks ago - AC Immune receives fast track designation, clearance for ACI-7104 IND - TheFly
- 5 weeks ago - AC Immune Earnings release: Q2 2026 - Filings
- 5 weeks ago - AC Immune First Half 2026 Financial and Corporate Update - GlobeNewsWire
- 2 months ago - AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - GlobeNewsWire
- 2 months ago - AC Immune announces interim data from first three cohorts of ABATE trial - TheFly
- 2 months ago - AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease - GlobeNewsWire
- 3 months ago - AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease - GlobeNewsWire